Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO4927350 |
Synonyms | |
Therapy Description |
RO4927350 is a non-ATP competitive inhibitor of MEK1/2, which may result in inhibition of cell proliferation and antitumor activity (PMID: 19244124). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO4927350 | MEK inhibitor (Pan) 26 | RO4927350 is a non-ATP competitive inhibitor of MEK1/2, which may result in inhibition of cell proliferation and antitumor activity (PMID: 19244124). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 F129L | colorectal cancer | sensitive | RO4927350 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440). | 21705440 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|